News
Adcentrx Receives China IND Nod for Next-Generation Cancer ADC
The NMPA clearance allows Adcentrx to include China-based clinical centres in its ongoing Phase 1a/1b trial evaluating the ADC in patients with late-stage solid tumours, including prostate cancer.
imphoenix82
- June 9, 2026
- 0 Comments
- 10 Views
-